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NOTES AND COMMENTS
Comparison of antimicrobial susceptibility test breakpoints
of national societies
A document by the European Committee on Antimicrobial
Susceptibility Testing, EUCAST, has recently been published
on the method of determination of antimicrobial susceptibility
test breakpoints [1]. (EUCAST is an official committee of the
European Society for Clinical Microbiology and Infectious
Diseases (ESCMID). The Breakpoint Subcommittee of
EUCAST comprisesJ.E. Degener and 1. Phillips (cochairmen),
F.Baquero, T. Bergan, A. Bryskier, F. Goldstein, G. C. Schito, S.
Sidorenko, L. Verbist and B. Wiedemann.) In the document,
the method described is that used by the former European
Study Group on Antimicrobial Breakpoints (ESGAB) and
subsequently by EUCAST. EUCAST represents the European
national scientific societies in order to obtain consensus break-
points for antibiotics.
In their recent note on 'Apparent differences in antimicrobial
susceptibility as a consequence of national guidelines',
Leegaard et al have highlighted the discrepant results caused
by the application of different interpretative guidelines for
susceptibility testing [2]. At the national level, these differences
may not have serious clinical implications, as long as there is a
direct relation between the breakpoints, the epidemiology of
resistant strains, the indications and the recommended dosing
regimens of antimicrobial drugs. However, apart from the
desirability of mutual scientific understanding, the most impor-
tant reason to pursue breakpoint consensus is the worldwide
resistance problem. As long as there is no agreement on how to
interpret MICs, it will remain impossible to make epidemio-
logically valid comparisons between countries. Unified break-
points will facilitate the comparison ofgeographic differences in
resistance prevalence and the correlation of these with
data on clinical impact, hygienic circumstances, and antibiotic
drug utilization. Furthermore, international disagreement on
susceptibility interpretation will raise confusion among
drug manufacturers and advisory boards which have to
make the recommendations on indications and dosing of anti-
biotics.
For the establishment of clinical breakpoints, information is
needed on the distribution ofMICs for susceptible and resistant
bacterial strains, on the pharmacodynamics and pharmacoki-
netics of the antibiotics under study, and on the clinical results
of antibiotic therapy in relation to susceptible or resistant
pathogens.
It is not surprising that different national study groups have,
to a certain extent, chosen a variety of breakpoints relating in
part to differences in the epidemiology ofbacterial resistance, in
dosing regimens or in patient populations between nations, but
also to differences in the weighting of the various factors
considered.
There is an urgent need to reach consensus.
The purpose ofthis note is to set out the differences between
the national antibiotic breakpoints used in Europe. It makes
clear the magnitude of the effort required within EUCAST
(and by all clinical microbiologists and infectious diseases
doctors) to reach consensus, both when the differences are
small (but nonetheless tenaciously defended) and when they are
large (in which case there is likely to be discussion on the wider
scientific background to the decisions).
In Europe, a number of national clinical microbiological
societies, infectious diseases societies or general institutes for
standardization have working groups which have been publish-
ing recommendations for susceptibility testing methods and
interpretation. They include the British Society for Antimi-
crobial Chemotherapy (BSAC) [3], the Commissie Richtlijnen
Gevoeligheids-bepalingen in The Netherlands (CRG) [4], the
Deutsches Institut fur Normung (DIN) [5], the Mesa Espanola
de N ormalizacion de la Susceptibilidad y Resistencia a los
Antimicrobianos (MENSURA) [6], the Norwegian Working
Group on Antibiotics (NWGA) [7], the Comite de l'antibio-
gramme de la Societe Francaise de Microbiologie (SFM) [8] and
the Swedish Reference Group for Antibiotics (SRGA) [9].
Several European countries use the guidelines of the Antibiotic
Susceptibility Testing Subcommittee of the National Commit-
tee for Clinical Laboratory Standards (NCCLS) [10]. Current
guidelines for a restricted number of'class' antibiotics are set out
in Table 1 for Enterobacteriaceae and in Table 2 for Gram-
positive organisms. In some systems a breakdown has been
made, e.g. for Pseudomonas spp., enterococci, coagulase-positive
and -negative staphylococci, and more fastidious organisms
such as pneumococci and Haemophilus spp. Where applicable,
this is demonstrated in Tables 1 and 2. The information in these
tables should not be used for practical laboratory or clinical
purposes, as more detailed recommendations from the original
papers had to be omitted and data shown may have been subject
to changes by the national committees. For practical purposes,
the most recently published national guidelines should be used.
However, these guidelines might not always be readily available,
one of the drawbacks of existing diverse local standards. There
are two striking differences between systems. First, there are
differences in the assignment of the characters <:::, ::;, and> to
the interpretations S and R. Second, although the differences
between the breakpoints for individual drugs are generally not
large for the European countries, the NCCLS-R breakpoints
are in general one or more steps higher. This might be
explained, in part, by the focus on two-step antibiotic dilution
methods in MIC tests. In this case, the intermediately suscep-
tible category lies one or more dilution steps below the R-Ievel
and no account is taken of continuous series. However the
SRGA, MENSURA, the NWGA and, recently, the BSAC and
DIN also use the characters <::: and ::;" comparable to the
NCCLS system, although the former do not have such high
R-breakpoints.
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~ Table 2 MIC breakpoints for Gram-positive organisms proposed by different national committees
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There is not much time left for extensive discussion on the
usefulness of generally accepted breakpoints for susceptibility
interpretation. Where there are minor differences between
breakpoints for individual drugs, it should not be too difficult
to reach consensus on common European breakpoints. How-
ever, the difficulty of the task should not inhibit attempts to
resolve greater differences, including those found in the widely
accepted NCCLS system. The final goal must be the establish-
ment and maintenance of a single international system of
breakpoints.
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